WallStreetZenWallStreetZen

NASDAQ: CPIX
Cumberland Pharmaceuticals Inc Stock

$2.60+0.01 (+0.39%)
Updated Feb 6, 2023
CPIX Price
$2.60
Fair Value Price
$4.41
Market Cap
$37.61M
52 Week Low
$1.89
52 Week High
$3.81
P/E
-5.53x
P/B
0.97x
P/S
0.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$41.21M
Earnings
-$6.98M
Gross Margin
76.2%
Operating Margin
-15.8%
Profit Margin
-16.9%
Debt to Equity
1.35
Operating Cash Flow
$7M
Beta
0.17
Next Earnings
Mar 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CPIX Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CPIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CPIX ($2.60) is undervalued by 41.1% relative to our estimate of its Fair Value price of $4.41 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CPIX ($2.60) is significantly undervalued by 41.1% relative to our estimate of its Fair Value price of $4.41 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CPIX due diligence checks available for Premium users.

Be the first to know about important CPIX news, forecast changes, insider trades & much more!

CPIX News

Valuation

CPIX fair value

Fair Value of CPIX stock based on Discounted Cash Flow (DCF)
Price
$2.60
Fair Value
$4.41
Undervalued by
41.10%
CPIX ($2.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CPIX ($2.60) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CPIX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CPIX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.53x
Industry
18.21x
Market
14.99x

CPIX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
1.9x
CPIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CPIX's financial health

Profit margin

Revenue
$11.4M
Net Income
-$408.6k
Profit Margin
-3.6%
CPIX's Earnings (EBIT) of -$6.51M... subscribe to Premium to read more.
Interest Coverage Financials
CPIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$90.8M
Liabilities
$52.3M
Debt to equity
1.35
CPIX's short-term assets ($49.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CPIX's short-term assets ($49.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CPIX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CPIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.6M
Investing
$680.8k
Financing
-$2.0M
CPIX's operating cash flow ($6.78M)... subscribe to Premium to read more.
Debt Coverage Financials

CPIX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
CPIX$37.61M+0.39%-5.53x0.97x
DERM$36.12M-16.73%-0.69x1.38x
ATNX$34.79M0.00%-0.14x1.40x
CRDL$42.21M-6.21%-2.02x0.99x
ADMP$33.00M0.00%-1.00x11.60x

Cumberland Pharmaceuticals Stock FAQ

What is Cumberland Pharmaceuticals's quote symbol?

NASDAQ: CPIX) Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol CPIX. Cumberland Pharmaceuticals stock quotes can also be displayed as NASDAQ: CPIX.

If you're new to stock investing, here's how to buy Cumberland Pharmaceuticals stock.

What is the 52 week high and low for Cumberland Pharmaceuticals (NASDAQ: CPIX)?

(NASDAQ: CPIX) Cumberland Pharmaceuticals's 52-week high was $3.81, and its 52-week low was $1.89. It is currently -31.72% from its 52-week high and 37.57% from its 52-week low.

How much is Cumberland Pharmaceuticals stock worth today?

(NASDAQ: CPIX) Cumberland Pharmaceuticals currently has 14,464,127 outstanding shares. With Cumberland Pharmaceuticals stock trading at $2.60 per share, the total value of Cumberland Pharmaceuticals stock (market capitalization) is $37.61M.

Cumberland Pharmaceuticals stock was originally listed at a price of $16.83 in Aug 11, 2009. If you had invested in Cumberland Pharmaceuticals stock at $16.83, your return over the last 13 years would have been -84.55%, for an annualized return of -13.38% (not including any dividends or dividend reinvestments).

How much is Cumberland Pharmaceuticals's stock price per share?

(NASDAQ: CPIX) Cumberland Pharmaceuticals stock price per share is $2.60 today (as of Feb 6, 2023).

What is Cumberland Pharmaceuticals's Market Cap?

(NASDAQ: CPIX) Cumberland Pharmaceuticals's market cap is $37.61M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cumberland Pharmaceuticals's market cap is calculated by multiplying CPIX's current stock price of $2.60 by CPIX's total outstanding shares of 14,464,127.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.